AIRS vs DBVT vs ALKS vs SKIN

For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.

2% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Alkermes plc (ALKS) offers the better valuation at 25. 3x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +64.

4%, compared to -92. 8% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ALKS returned -7. 7% versus SKIN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus AirSculpt Technologies, Inc. 's 3. 37β — meaning AIRS is approximately 218% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.

2% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, AIRS leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -4. 6% for AirSculpt Technologies, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — ALKS leads at 86. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, AIRS (0.

1% yield) pays a dividend. DBVT, ALKS, SKIN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -7. 7%, SKIN: -91. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AIRS (Healthcare) and DBVT (Healthcare) and ALKS (Unknown) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.